Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2023-04-28 Share Issue/Capital Cha…
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
Datos cierre operación dividendo flexible
Share Issue/Capital Change Classification · 98% confidence The document is an official communication ('OTRA INFORMACIÓN RELEVANTE') addressed to the Spanish National Securities Market Commission ('COMISIÓN NACIONAL DEL MERCADO DE VALORES'). The content details the final results of a flexible dividend scheme ('Dividendo flexible con cargo a 2022') involving the allocation of free warrants, the sale of rights back to the company, and the subsequent issuance of new shares via a capital increase ('ampliación de capital liberada'). This clearly relates to changes in capital structure, share issuance, and financing activities. While it involves a dividend (DIV) and share issuance (SHA), the core subject is the completion and mechanics of the capital increase resulting from the flexible dividend option. Since it explicitly details the issuance of new shares ('el número de acciones nuevas que se emitirán en este aumento de capital liberado será de 10.882.226 acciones'), the most precise classification is Share Issue/Capital Change (SHA). It is not a general announcement of a dividend amount (DIV), but the mechanics of the capital change resulting from the dividend choice.
2023-04-28 Spanish
Informe de negocio primer trimestre 2023
Investor Presentation Classification · 99% confidence The document is titled "Informe de negocio Q1 2023" (Business Report Q1 2023) and contains a detailed 'Índice' (Index) covering 'Resumen financiera' (Financial Summary), 'Evolución Negocios Q1 2023' (Business Evolution Q1 2023), R&D updates, and a full 'Cuenta de resultados' (Income Statement) comparing Q1 2023 to Q1 2022. The content is comprehensive, covering operational performance, financial metrics, and future outlook for a specific interim period (Q1). This structure strongly indicates a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not the full annual report (10-K).
2023-04-26 Spanish
Presentación a analistas
Investor Presentation Classification · 98% confidence The document is titled 'Capital Markets Day 29 de marzo 2023' and contains detailed slides covering strategic pillars, product families (Bilastina, Calcifediol, Mesalazina), commercialization platforms (Farma Iberia, LATAM, OMA), operational excellence (Plan Industrial), and R&D strategy. This structure—a formal presentation outlining strategy, performance review (2022 results), and future outlook—is characteristic of an Investor Presentation (IP) or a presentation delivered during an investor event like a Capital Markets Day. Since 'Capital Markets Day' is a specific type of investor event, 'Investor Presentation' (IP) is the most appropriate classification, as it represents the core material being presented to investors.
2023-03-29 Spanish
Aprobación del dividendo flexible
Share Issue/Capital Change Classification · 98% confidence The document is a formal communication addressed to the 'COMISIÓN NACIONAL DEL MERCADO DE VALORES' (CNMV, the Spanish securities market regulator) under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content details the execution of a capital increase ('aumento de capital') linked to a flexible dividend scheme ('dividendo flexible') approved previously by the General Shareholders' Meeting. It also mentions an associated share repurchase program ('programa de recompra de acciones'). Crucially, the document includes an attached 'DOCUMENTO INFORMATIVO' detailing the terms and conditions of the capital increase, including the calculation formulas, calendar, and shareholder options (receive shares or cash). This document is not the full Annual Report (10-K), nor is it just a brief Earnings Release (ER). It is a detailed disclosure regarding a significant corporate action involving capital structure changes (share issuance/dividend alternative) and financing. The options that fit best are 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the primary focus is the execution and detailed terms of a capital increase (a financing activity) resulting from a flexible dividend, 'CAP' (Capital/Financing Update) is highly appropriate. However, the action explicitly involves issuing new shares ('aumento de capital'), which directly maps to 'SHA' (Share Issue/Capital Change). Given the detailed nature of the share issuance mechanics (rights allocation, calculation formulas, calendar for new share listing), SHA is the most precise fit for the core event described, even though it is framed as part of a dividend payment mechanism. It is a comprehensive disclosure document, not just a short announcement of publication (RPA/RNS). Therefore, I classify it as a Share Issue/Capital Change (SHA).
2023-03-27 Spanish
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2022
Remuneration Information Classification · 100% confidence The document text is highly structured and focuses entirely on the 'POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD PARA EL EJERCICIO EN CURSO' (Remuneration Policy for the Current Fiscal Year) for FAES FARMA, S.A. It details the procedures, external advisors (WillisTowersWatson, Georgeson), comparison groups, mix of fixed vs. variable pay, long-term incentive plans (3-year framework), and risk mitigation measures related to executive compensation. This content directly corresponds to the disclosure requirements for executive and director remuneration, which is specifically covered by the DEF 14A filing category (Proxy Solicitation/Information Statement focusing on Remuneration, often referred to as a 'Say-on-Pay' report in some jurisdictions, although the definition provided maps it directly to Remuneration Information). Although the document discusses the policy for the current exercise (2023, based on the 2022 year-end date mentioned), the detailed nature and structure strongly suggest it is the annual report on remuneration required to be presented to shareholders, which aligns best with the 'Remuneration Information' definition (DEF 14A). It is not a general Annual Report (10-K) as it lacks comprehensive operational and financial statements, nor is it a simple Earnings Release (ER) or a general Regulatory Filing (RNS).
2023-02-28 Spanish
Corporate Governance Report - Faes Farma S.A.
Remuneration Information Classification · 100% confidence The document text explicitly discusses the 'Política de Remuneraciones de los Consejeros' (Directors' Remuneration Policy) for the current fiscal year (ending 31/12/2022), detailing procedures, external advisors (WillisTowersWatson, Georgeson), the remuneration mix (fixed vs. variable), long-term incentive plans, and risk mitigation measures related to executive pay. This content directly corresponds to the definition of Remuneration Information, which is classified as DEF 14A (Proxy Solicitation & Information Statement often contains this, but the specific focus here is remuneration disclosure, which aligns best with DEF 14A in the provided list, although DEF 14A is formally the Proxy Statement, the content here is the remuneration report section often found within or alongside it, or as a standalone report mandated by Spanish corporate governance codes, which maps closely to the remuneration disclosure category). Given the options, 'DEF 14A' is the closest fit for detailed executive compensation disclosure, even if the document structure might resemble a Spanish 'Informe Anual de Gobierno Corporativo' (which is not an option, but DEF 14A covers remuneration reports in the US context). Since the content is entirely focused on remuneration policy and structure, DEF 14A is the most appropriate classification among the choices.
2023-02-28 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.